^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gallbladder Cancer
    Regimen:GC (cisplatin + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Neoadjuvant therapy (for gallbladder cancer only)…Other recommended regimens…Gemcitabine + cisplatin
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Eur J Cancer
    Title:

    Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

    Published date:
    11/07/2019
    Excerpt:
    Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer...Median OS in mGemOx was 9 months and 8·3 months in CisGem; p = 0·057 (hazard ratio = 0·78; 95% CI = 0·60-1·02). Restricted mean OS for follow-up limited to 30 months was 11·2 months (95% CI: 9·8–12·6) in mGemOx and 10·4 months (95% CI: 9·1–11·7) in CisGem....Numerically OS was better with mGemOx.
    DOI:
    doi.org/10.1016/j.ejca.2019.10.004
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    N Engl J Med
    Title:

    Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

    Published date:
    04/08/2010
    Excerpt:
    ...patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin...followed by gemcitabine...or gemcitabine alone...the median overall survival was 11.7 months among the 204 patients in the cisplatin-gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001).
    DOI:
    10.1056/NEJMoa0908721